For example, Imatinib, a selective inhibitor of BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia and is considered a standard first line treatment [20]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.